Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potential predictive value of SCN4A mutation status for immune checkpoint inhibitors in melanoma.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Nov 2020

Lin Weiyin, Lin Anqi, Li Zhefu, Zhou Chaozheng, Chen Chufeng, Chen Boliang, Lyu Qingwen, Zhang Jian, Luo Peng

Abstract excerpt

Melanoma refers to a pigmented nevus with malignant changes. The preferred treatment for primary melanoma is surgical excision and postoperative radiotherapy, but the prognosis is poor. Immune checkpoint inhibitors (ICIs) have been remarkably successful in different types of cancers, but not all cancer patients can benefit from it. Therefore, it is essential to find predictable biomarkers and improve the accuracy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cohort Studies
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Melanoma

Share to NAV1.4 Voltage-Gated Sodium Channel

Share to Predictive Value of Tests

Share to Skin Neoplasms

Source

Identifiers

PMID: 32892029
DOI: 10.1016/j.biopha.2020.110633

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potential predictive value of SCN4A mutation status for immune checkpoint inhibitors in melanoma.PMID 32892029Read ↗

CACNA1C mutation as a prognosis predictor of immune checkpoint inhibitor in skin cutaneous melanoma.Semantic proximity Read ↗

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.Semantic proximity Read ↗

Establishment and Evaluation of Immune Checkpoint Inhibitor Treatment Response Model Based on Gene Expression ValueSemantic proximity Read ↗

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.Semantic proximity Read ↗

Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy.Semantic proximity Read ↗

Identification of an Immune-Related Prognostic Signature Associated With Immune Infiltration in MelanomaSemantic proximity Read ↗

Molecular Profiling of Core Immune-Escape Genes Highlights LCK Has Potential to Reshape TME in MelanomaSemantic proximity Read ↗

Characterization of Aging-Related Genes to Predict Prognosis and Evaluate the Tumor Immune Microenvironment in Malignant MelanomaSemantic proximity Read ↗

Identification of an Immune-Related Prognostic Signature Associated with Immune Infiltration in MelanomaSemantic proximity Read ↗

Genomic and transcriptomic analyses of melanoma in Japanese patients reveal candidate biomarkers for immune checkpoint inhibitor respondersSemantic proximity Read ↗

Association of EYS mutations with immune checkpoint inhibitor outcome and response in melanoma and non-small cell lung cancerSemantic proximity Read ↗

Comprehensive insights on genetic alterations and immunotherapy prognosis in Chinese melanoma patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.